Pseudo-diffusion effects in lung MRI

Alveolar membrane and capillary function in COVID-19 convalescents: insights from chest MRI

OBJECTIVES

To investigate potential presence and resolution of longer-term pulmonary diffusion limitation and microvascular perfusion impairment in COVID-19 convalescents.

MATERIALS AND METHODS

This prospective, longitudinal study was carried out between May 2020 and April 2023. COVID-19 convalescents repeatedly and age/sex-matched healthy controls once underwent MRI including hyperpolarized 129Xe MRI. Blood samples were obtained in COVID-19 convalescents for immunophenotyping. Ratios of 129Xe in red blood cells (RBC), tissue/plasma (TP), and gas phase (GP) as well as lung surface-volume ratio were quantified and correlations with CD4+/CD8+ T cell frequencies were assessed using Pearson's correlation coefficient. Signed-rank tests were used for longitudinal and U tests for group comparisons.

RESULTS

Thirty-five participants were recruited. Twenty-three COVID-19 convalescents (age 52.1 ± 19.4 years, 13 men) underwent baseline MRI 12.6 ± 4.2 weeks after symptom onset. Fourteen COVID-19 convalescents underwent follow-up MRI and 12 were included for longitudinal comparison (baseline MRI at 11.5 ± 2.7 weeks and follow-up 38.0 ± 5.5 weeks). Twelve matched controls were included for comparison. In COVID-19 convalescents, RBC-TP was increased at follow-up (p = 0.04). Baseline RBC-TP was lower in patients treated on intensive care unit (p = 0.03) and in patients with severe/critical disease (p = 0.006). RBC-TP correlated with CD4+/CD8+ T cell frequencies (R = 0.61/ - 0.60) at baseline. RBC-TP was not significantly different compared to matched controls at follow-up (p = 0.25).

CONCLUSION

Impaired microvascular pulmonary perfusion and alveolar membrane function persisted 12 weeks after symptom onset and resolved within 38 weeks after COVID-19 symptom onset.

CLINICAL RELEVANCE STATEMENT

129Xe MRI shows improvement of microvascular pulmonary perfusion and alveolar membrane function between 11.5 ± 2.7 weeks and 38.0 ± 5.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease.

KEY POINTS

• The study aims to investigate long-term effects of COVID-19 on lung function, in particular gas uptake efficiency, and on the cardiovascular system. • In COVID-19 convalescents, the ratio of 129Xe in red blood cells/tissue plasma increased longitudinally (p = 0.04), but was not different from matched controls at follow-up (p = 0.25). • Microvascular pulmonary perfusion and alveolar membrane function are impaired 11.5 weeks after symptom onset in patients after COVID-19, returning to normal in subjects without significant prior disease at 38.0 weeks.

Influence of flow and susceptibility effects on spin dephasing in lung tissue

PURPOSE

Magnetic resonance imaging (MRI) of the lung can be used for diagnosis and monitoring of interstitial lung disease. Biophysical models of alveolar lung tissue are needed to understand the complex interplay of susceptibility, diffusion, and flow effects, and their influence on magnetic resonance (MR) spin dephasing.

METHODS

In this work, we present a method for modeling the signal decay of lung tissue by utilizing a two-compartment model, which considers the different spin dephasing mechanisms in the alveolar vasculature and interstitial tissue. This allows calculating the magnetization dynamics and the MR lineshape, which can be measured noninvasively using clinical MR scanners.

RESULTS

The accuracy of the method was evaluated using finite element simulations and the experimentally measured lineshapes of a healthy volunteer. In this comparison, the model performs well, indicating that the relevant spin dephasing mechanisms are correctly taken into account.

CONCLUSIONS

The proposed method can be used to estimate the influence of blood flow and alveolar geometry on the MR lineshape of lung tissue.

Effects of neonatal lung abnormalities on parenchymal R2 * estimates

Infants admitted to the neonatal intensive care unit (NICU) often suffer from multifaceted pulmonary morbidities that are not well understood. Ultrashort echo time (UTE) magnetic resonance imaging (MRI) is a promising technique for pulmonary imaging in this population without requiring exposure to ionizing radiation. The aims of this study were to investigate the effect of neonatal pulmonary disease on R₂ * and tissue density and to utilize numerical simulations to evaluate the effect of different alveolar structures on predicted R₂ *.This was a prospective study, in which 17 neonatal human subjects (five control, seven with bronchopulmonary dysplasia [BPD], five with congenital diaphragmatic hernia [CDH]) were enrolled. Twelve subjects were male and five were female, with postmenstrual age (PMA) at MRI of 39.7 ± 4.7 weeks. A 1.5T/multiecho three-dimensional UTE MRI was used. Pulmonary R₂ * and tissue density were compared across disease groups over the whole lung and regionally. A spherical shell alveolar model was used to predict the expected R₂ * over a range of tissue densities and tissue susceptibilities. Tests for significantly different mean R₂ * and tissue densities across disease groups were evaluated using analysis of variance, with subsequent pairwise group comparisons performed using t tests. Lung tissue density was lower in the ipsilateral lung in CDH compared to both controls and BPD patients (both p < 0.05), while only the contralateral lung in CDH (CDHc) had higher whole-lung R₂ * than both controls and BPD (both p < 0.05). R₂ * differences were significant between controls and CDHc within all tissue density ranges (all p < 0.05) with the exception of the 80%-90% range (p = 0.17). Simulations predicted an inverse relationship between alveolar tissue density and R₂ * that matches empirical human data. Alveolar wall thickness had no effect on R₂ * independent of density (p = 1). The inverse relationship between R₂ * and tissue density is influenced by the presence of disease globally and regionally in neonates with BPD and CDH in the NICU. LEVEL OF EVIDENCE: 2. TECHNICAL EFFICACY STAGE: 2.